![]() ![]() New PIONEER-HF and TRANSITION-HF findings will advance understanding of Entresto use in patients hospitalized for decompensated HFrEF following stabilizationīasel, AugNovartis will present data for Entresto (sacubitril/valsartan) in both types of chronic heart failure - HFpEF and HFrEF - at the upcoming ESC Congress 2019, the annual meeting of the European Society of Cardiology (ESC), taking place from August 31 to September 4 in Paris.New PROVE-HF and EVALUATE-HF studies will highlight Entresto’s direct impact on the heart in heart failure with reduced ejection fraction (HFrEF).PARAGON-HF trial will provide Entresto (sacubitril/valsartan) Phase III full results in heart failure with preserved ejection fraction (HFpEF).degree of university continuing education.announce a continuing education program.search a university continuing education program.navigate in the swiss science landscape.scientific publications and open access.job offers for scientists and engineers. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |